CD8A and neoplasm: 35 The most recent CD73 inhibitor, compound 8, effectivelysuppresses AMP-mediated CD8+ T cells and tumor growth eitheras a monotherapy or in combination with chemotherapy (oxaliplatin,doxorubicin, or docetaxel) or a checkpoint inhibitor in preclinical in vitro/in vivo studies.36